Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss
Zacks Investment Research | Nov 04, 2019 11:41PM ET
Mylan N.V. (NASDAQ:MYL) reported adjusted earnings of $1.17 cents per share in the third quarter of 2019, which beat the Zacks Consensus Estimate of $1.14 but declined from $1.25 reported in the year-ago quarter.
However, third-quarter revenues of $2.96 billion missed the Zacks Consensus Estimate of $3.03 billion. Revenues increased 3% reportedly and 6% at constant exchange rate (“CER”) from the prior-year quarter.
Shares of the company increased 1.7% in pre-market trading following the earnings release. However, Mylan’s stock has declined 28% year to date compared with the industry ’s decrease of 1%.
Quarter in Detail
The company posts results in three segments on a geographic basis — North America, Europe and Rest of World.
North America segment’s net sales came in at $1.09 billion, up 8% year over year. The growth was driven by higher sales of new products, especially Wixela Inhub and Yupleri. This was partially offset by lower sales of existing products due to lower volumes as well as lower pricing and changes in the competitive environment, including loss of exclusivity on tadalafil.
Net sales in the Europe segment were $1.05 billion, up less than 1% on the back of higher sales of new products including Hulio, and higher volumes of existing products. However, it was partially offset by unfavorable impact of foreign currency translation and lower pricing on existing products. Net sales in the segment were up 6% at CER.
Rest of World segment net sales of $793.7 million were up 3%, driven by new product sales and higher volumes of existing products. This was partially offset by lower pricing on existing products and unfavorable impact of foreign currency translation. Net sales were up 4% at CER.
Adjusted gross margin of 53% declined from 55% in the year-ago quarter.
2019 Guidance
The company updated its guidance for 2019. Revenues are projected between $11.5 billion and $12 billion compared with the previously expected range of $11.5 billion - $12.5 billion. The Zacks Consensus Estimate is pegged at $11.66 billion.
The company anticipates adjusted EPS around $4.20-$4.40 (previously $3.80-$4.80). The Zacks Consensus Estimate is pegged at $4.26.
Our Take
Mylan’s third-quarter earnings beat estimates but sales missed the same. While the generics market experienced a slowdown due to pricing pressure in major markets, the company’s new products did well in the quarter. Moreover, it is on track to launch a biosimilar version of Roche’s (OTC:RHHBY) blockbuster cancer drug, Herceptin. Meanwhile, the company’s decision to merge with Upjohn, Pfizer's (NYSE:PFE) off-patent branded and generic established medicines business is also encouraging.
However, rising competition and continued supply constraints for EpiPen remains a concern. We note that rival Teva Pharmaceutical (NYSE:TEVA) has already won FDA approval for the first generic version of Mylan’s EpiPen and EpiPen Jr, which, in turn, will unfavorably impact sales further.
Get The News You Want
Mylan N.V. Price, Consensus and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.